Taipei, Taiwan

Pei-Wen Shan


 


Average Co-Inventor Count = 6.2

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Zhonghe, TW (2014)
  • New Taipei, TW (2016 - 2017)

Company Filing History:


Years Active: 2014-2017

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: Pei-Wen Shan: Innovator in Medicinal Chemistry

Introduction

Pei-Wen Shan is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of novel compounds for treating serious health conditions. With a total of three patents to his name, Shan's work is recognized for its potential impact on cancer treatment and heart failure.

Latest Patents

Shan's latest patents include innovative compounds such as indolyl or indolinyl hydroxamate compounds. These compounds are defined by specific formulas and are disclosed for their method of treating cancer. Additionally, he has developed the use of indolyl and indolinyl hydroxamates for treating heart failure and neuronal injury. These small molecules are highlighted as lead compounds for manufacturing medicaments or pharmaceutical compositions aimed at patients suffering from these conditions.

Career Highlights

Throughout his career, Pei-Wen Shan has worked with esteemed institutions such as Taipei Medical University and The Ohio State University. His research has focused on the synthesis and application of small molecules in therapeutic settings, showcasing his dedication to advancing medical science.

Collaborations

Shan has collaborated with notable colleagues, including Jing-Ping Liou and Kuo-Sheng Hung. These partnerships have contributed to the development and refinement of his innovative compounds.

Conclusion

Pei-Wen Shan's work in medicinal chemistry exemplifies the importance of innovation in healthcare. His patents reflect a commitment to addressing critical health issues through scientific research and collaboration.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…